# Sunbird Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sunbird-bio

- Industry: Medical Devices & Equipment
- Headquarters: Cambridge, US
- Website: www.sunbirdbio.com
- Total disclosed funding: $52M
- Latest round: Series A (Apr 27, 2023)
- Investors on record: 6

## About

Based in Massachusetts, US, and founded in 2021, Sunbird Bio, Inc. operates as a biotechnology company that offers a diagnostics platform that develops tests for molecular diagnostics which helps in the diagnosis and treatment of Alzheimer’s disease, other neurological disorders, and early-stage cancer. The company was Co-founded by Huilin Shao, Carine Lim, and Nicholas Ho.In October 2024, Sunbird Bio, Inc. raised USD 14 million from new investors EDBI and Eli Lilly & Company, with participation from returning investors Clavystbio, Polaris Partners, and Section 32. As of 2023, the company is led by its CEO and executive chairman John McDonough.

The core platforms provided by the company are the APEX platform and Glymps. APEX is a diagnostic platform for detecting very low levels of nanoscale, disease-specific protein states in blood. It detects protein aggregates that are associated with several neurodegenerative diseases and provides both patients and practitioners. The Glympse platform offered by the firm uses peptide probes to capture signals and it measures and analyzes the activity of specific proteases in the blood and correlates this activity with the presence and progression of disease.

## Funding rounds

- Series A, Apr 27, 2023, $23M — Polaris Partners, SG Growth Capital, Eli Lilly & Company, Section 32, ClavystBio
- Seed, Nov 3, 2022, $11M — Polaris Partners, ClavystBio
- Series B, Dec 2, 2021, $18M — Alumni Ventures Group

## Investors

- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed, Series A
- ClavystBio (https://capitalatlas.ai/funds/clavystbio) — Seed, Series A
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series A
- Eli Lilly & Company — Series A
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series A